Antibiotic prescribing practices during the COVID-19 pandemic: A post-hoc analysis of the Adaptive COVID-19 Treatment Trial
Clicks: 3
ID: 324944
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
3 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #92 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background The COVID-19 pandemic exacerbated antibiotic overuse; however, gaps remain regarding the timing of administration and whether prescribing is supported by evidence of bacterial infection. Methods Antibiotic use was described within the Adaptive COVID-19 Treatment Trial (ACTT), a series of randomized controlled therapeutics trials in adults hospitalized with COVID-19 from Feb 2020-May 2021. Proportions of participants receiving antibiotics by trial stage were described (overall, pre-randomization, post-randomization). Analyses were repeated for CDC’s National Healthcare Safety Network (NHSN) categories and for antibiotics used for community-acquired pneumonia (CAP) according to IDSA guidelines. In ACTT-2 and ACTT-4, lab culture results were documented for Grade 3 or greater infection adverse events; proportions of antibiotic recipients with a positive culture were compared between trials. Results Most (62%) of the 4,074 participants received at least one antibiotic. Pre-randomization antibiotic use declined across ACTT stages, from 72% in ACTT-1 to 32% in ACTT-4. The largest decrease noted is within the NHSN category for community-acquired infection (decreasing significantly from 49% in ACTT-1 to 24% in ACTT-4). Post-randomization use was lower and declined modestly, from 28% to 18%. The percentage of post-randomization antibiotic recipients with a positive bacterial culture was 18% in ACTT-2 and 18% in ACTT-4. Conclusions Antibiotic use decreased substantially over the first pandemic year, however in-hospital prescribing remained common despite limited microbiologic confirmation of infection. Stewardship efforts during future respiratory viral pandemics should focus on reducing empiric antibiotic use for CAP-like illness at presentation and on strengthening reassessment, diagnostic stewardship, and de-escalation of later in-hospital antibiotic therapy.
| Reference Key |
openalex_W7202357585
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Catharine I. Paules, Kevin Rubenstein, Kay M. Tomashek, Tyler Bonnett, Nadine Rouphael, Zanthia Wiley, Varduhi Ghazaryan, Rekha R. Rapaka, Gail E. Potter |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag503
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.